Skip to main content

Table 2 Clinical parameters of patients with MMN (N = 124), stratified by IgM anti-GM1 and anti-GM2 antibody status

From: IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset

 

Patient groups

p-values

(A) Anti-GM2 +

(B) Anti-GM1+

(C) Anti-GM2/GM1-

A vs. B

A vs. C

N = 13

N = 63

N = 48

IgM anti-GM1 IgM positive (n (%))

9 (69)

63 (100)

0 (0)

-

-

IgM anti-GM2 IgM positive (n (%))

13 (100)

0 (0)

0 (0)

-

-

Male sex (n (%))

10 (77)

47 (75)

36 (75)

1.00

1.00

EFNS MMN diagnosis (n (%))

   

0.88

0.54

 Definite

10 (77)

42 (67)

36 (77)

  

 Probable

3 (23)

16 (25)

7 (15)

  

 Possible

0 (0)

5 (8)

4 (8)

  

Age at onset (median years (IQR))

31 (16)

43 (13)

42 (14)

0.015*

0.034*

Inclusion MAIN 2007 (n (%))

12 (92)

50 (79)

25 (52)

-

-

Inclusion MAIN 2015 (n (%))

10 (77)

43 (68)

41 (85)

-

-

Inclusion MAIN 2007 & MAIN 2015 (n (%))

9 (69)

30 (47)

20 (42)

-

-

Disease duration (median months (IQR))

     

 At first UMCU visit

57 (96)

49 (80)

32 (63)

0.36

0.037*

 MAIN 2007

216 (120)

132 (141)

120 (96)

0.13

0.042*

 MAIN 2015

308 (170)

216 (182)

166 (122)

0.16

0.008*

Nerve conduction studies at diagnosis

     

 Conduction block (n (%))

12 (93)

50 (93)

43 (96)

1.00

0.54

 Definite conduction block (n (%))

9 (69)

34 (63)

36 (80)

0.76

0.46

 Axonal damage (n (%))

7 (54)

24 (44)

13 (29)

0.55

0.11

 Nerves with CB (median (range))

2 (0–9)

3 (0–12)

3 (0–14)

0.94

0.90

 Nerves with definite CB (median (range))

1 (0–5)

1 (0–5)

1 (0–8)

0.68

0.84

 Nerves with axonal damage (median (range))

1 (0–7)

0 (0–7)

0 (0–3)

0.73

0.31

IVIg treatment (n (%))

     

 At first UMCU visit

5 (42)

16 (25)

4 (9)

0.30

0.015*

 MAIN 2007

10 (83)

39 (78)

17 (68)

1.00

0.44

 MAIN 2015

10 (100)

39 (91)

15 (75)

1.00

0.14

IVIg dosage (median gr/month (IQR))

     

 MAIN 2007

18 (9)

14 (8)

12 (7)

0.33

0.16

 MAIN 2015

20 (8)

15 (10)

10 (7)

0.85

0.08

Monoclonal gammopathy (n (%))

     

 IgM

1 (8)

6 (10)

3 (7)

1.00

1.00

 IgG

0 (0)

2 (3)

2 (5)

1.00

1.00

CSF studies performed (n (%))

2 (15)

15 (26)

15 (31)

0.72

0.48

 CSF elevated protein level

2 (100)

15 (100)

9 (60)

1.00

0.51

 CSF leukocytosis

0 (0)

0 (0)

1 (14)

-

-

Brachial plexus MRI abnormalities (n (%))

7 (78)

17 (45)

10 (33)

0.14

0.026*

MRC sum score (median (IQR))

     

 At first UMCU visit

115 (4)

121 (9)

124 (8)

0.12

0.0003*

 ΔMRCss (MAIN 2007–2015)

-8 (9)

-11 (10)

-4 (7)

0.41

0.13

Postural tremor (n (%))

8 (80)

27 (64)

25 (63)

0.47

0.46

Sensory abnormalities (n (%))

     

 Hypesthesia/paresthesia

4 (33)

3 (6)

4 (16)

0.023*

0.39

 Vibration sense abnormalities

3 (25)

13 (26)

3 (12)

1.00

0.37

  1. * Statistically significant at p-value < 0.05
  2. All analyses concerning IVIg dosage and MRC sum scores were corrected for disease duration. Analyses concerning the MRC sum score at patients’ first visit to the UMCU were performed in treatment-naïve patients only
  3. CB = conduction block, CSF = cerebrospinal fluid, IVIg = intravenous immunoglobulins, MMN = multifocal motor neuropathy, MRCss = MRC sum score, MRI = magnetic resonance imaging
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094